184 related articles for article (PubMed ID: 28735890)
1. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
van Beers EH; van Vliet MH; Kuiper R; de Best L; Anderson KC; Chari A; Jagannath S; Jakubowiak A; Kumar SK; Levy JB; Auclair D; Lonial S; Reece D; Richardson P; Siegel DS; Stewart AK; Trudel S; Vij R; Zimmerman TM; Fonseca R
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):555-562. PubMed ID: 28735890
[TBL] [Abstract][Full Text] [Related]
2. Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.
Chen YT; Valent ET; van Beers EH; Kuiper R; Oliva S; Haferlach T; Chng WJ; van Vliet MH; Sonneveld P; Larocca A
Int J Lab Hematol; 2022 Feb; 44(1):127-134. PubMed ID: 34448362
[TBL] [Abstract][Full Text] [Related]
3. Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma.
van Beers EH; Huigh D; Bosman L; de Best L; Kuiper R; Spaan M; van Duin M; Sonneveld P; Dumee B; van Vliet MH
J Mol Diagn; 2021 Jan; 23(1):120-129. PubMed ID: 33152501
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.
Kuiper R; Zweegman S; van Duin M; van Vliet MH; van Beers EH; Dumee B; Vermeulen M; Koenders J; van der Holt B; Visser-Wisselaar H; Hansson M; van der Velden AWG; Beverloo HB; Stevens-Kroef M; Levin MD; Broijl A; Waage A; Sonneveld P
Blood Adv; 2020 Dec; 4(24):6298-6309. PubMed ID: 33351127
[TBL] [Abstract][Full Text] [Related]
5. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
Kuiper R; van Duin M; van Vliet MH; Broijl A; van der Holt B; El Jarari L; van Beers EH; Mulligan G; Avet-Loiseau H; Gregory WM; Morgan G; Goldschmidt H; Lokhorst HM; Sonneveld P
Blood; 2015 Oct; 126(17):1996-2004. PubMed ID: 26330243
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
Han W; Jin Y; Xu M; Zhao SS; Shi Q; Qu X; Zhang R; Li J; Wu Y; Chen L
Hematology; 2021 Dec; 26(1):510-517. PubMed ID: 34314294
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
8. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.
Kleber M; Ihorst G; Gross B; Koch B; Reinhardt H; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):541-51. PubMed ID: 23810244
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
[TBL] [Abstract][Full Text] [Related]
11. Low-risk identification in multiple myeloma using a new 14-gene model.
Chen T; Berno T; Zangari M
Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863
[TBL] [Abstract][Full Text] [Related]
12. Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.
Kjeldsen E
Cancer Genomics Proteomics; 2016; 13(2):91-127. PubMed ID: 26912802
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
16. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma.
Sedlarikova L; Gromesova B; Kubaczkova V; Radova L; Filipova J; Jarkovsky J; Brozova L; Velichova R; Almasi M; Penka M; Bezdekova R; Stork M; Adam Z; Pour L; Krejci M; Kuglík P; Hajek R; Sevcikova S
Eur J Haematol; 2017 Sep; 99(3):223-233. PubMed ID: 28543758
[TBL] [Abstract][Full Text] [Related]
17. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
18. Improved risk stratification in myeloma using a microRNA-based classifier.
Wu P; Agnelli L; Walker BA; Todoerti K; Lionetti M; Johnson DC; Kaiser M; Mirabella F; Wardell C; Gregory WM; Davies FE; Brewer D; Neri A; Morgan GJ
Br J Haematol; 2013 Aug; 162(3):348-59. PubMed ID: 23718138
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
Zhou M; Zhao H; Wang Z; Cheng L; Yang L; Shi H; Yang H; Sun J
J Exp Clin Cancer Res; 2015 Sep; 34(1):102. PubMed ID: 26362431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
